What do systematic reviews say?

Systemic antifungal vs placebo/no treatment

Systemic antifungal showed no clear difference in adverse effects ‐ hepatic toxicity compared with placebo/no treatment (low certainty).

• Topical and systemic antifungal therapy for chronic rhinosinusitis 2018 · Cochrane Headline outcomes only
  RR 3.35 [0.14, 78.6]
  Studies not reported
  Low

Systemic antifungal vs placebo/no treatment

Systemic antifungal showed no clear difference in adverse effects ‐ gastrointestinal disturbances compared with placebo/no treatment (low certainty).

• Topical and systemic antifungal therapy for chronic rhinosinusitis 2018 · Cochrane Headline outcomes only
  RR 0.37 [0.04, 3.36]
  Studies not reported
  Low

Systemic antifungal vs placebo/no treatment

The review found no eligible studies for this question.

• Topical and systemic antifungal therapy for chronic rhinosinusitis 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Systemic antifungal vs placebo/no treatment

The review found no eligible studies for this question.

• Topical and systemic antifungal therapy for chronic rhinosinusitis 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Systemic antifungal vs placebo/no treatment

• Topical and systemic antifungal therapy for chronic rhinosinusitis 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  Low

Systemic antifungal vs placebo/no treatment

• Topical and systemic antifungal therapy for chronic rhinosinusitis 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  Low

Untargeted antifungal treatment with any antifungal drug (systemic or nonabsorbable) vs Placebo, no treatment, or another active antifungal intervention

Untargeted antifungal treatment with any antifungal drug (systemic… showed no clear difference in total (all‐cause) mortality compared with placebo/no antifungal/any other antifungal (moderate certainty).

• Antifungal agents for preventing fungal infections in non‐neutropenic critically ill patients 2016 · Cochrane Headline outcomes only
  RR 0.93 [0.79, 1.09]
  19 studies · 2374 participants
  Moderate

Untargeted antifungal treatment with any antifungal drug (systemic or nonabsorbable) vs Placebo, no treatment, or another active antifungal intervention

Untargeted antifungal treatment with any antifungal drug (systemic… may leads to lower proven invasive fungal infection compared with placebo/no antifungal/any other antifungal (low certainty).

• Antifungal agents for preventing fungal infections in non‐neutropenic critically ill patients 2016 · Cochrane Headline outcomes only
  RR 0.57 [0.39, 0.83]
  17 studies · 2024 participants
  Low

Untargeted antifungal treatment with any antifungal drug (systemic or nonabsorbable) vs Placebo, no treatment, or another active antifungal intervention

Untargeted antifungal treatment with any antifungal drug (systemic… showed no clear difference in superficial fungal infection compared with placebo/no antifungal/any other antifungal (low certainty).

• Antifungal agents for preventing fungal infections in non‐neutropenic critically ill patients 2016 · Cochrane Headline outcomes only
  RR 0.69 [0.37, 1.29]
  5 studies · 662 participants
  Low

Untargeted antifungal treatment with any antifungal drug (systemic or nonabsorbable) vs Placebo, no treatment, or another active antifungal intervention

Untargeted antifungal treatment with any antifungal drug (systemic… may leads to lower fungal colonization compared with placebo/no antifungal/any other antifungal (low certainty).

• Antifungal agents for preventing fungal infections in non‐neutropenic critically ill patients 2016 · Cochrane Headline outcomes only
  RR 0.71 [0.52, 0.97]
  12 studies · 1030 participants
  Low

Untargeted antifungal treatment with any antifungal drug (systemic or nonabsorbable) vs Placebo, no treatment, or another active antifungal intervention

Untargeted antifungal treatment with any antifungal drug (systemic… showed no clear difference in adverse events requiring cessation of study drug(s) compared with placebo/no antifungal/any other antifungal (low certainty).

• Antifungal agents for preventing fungal infections in non‐neutropenic critically ill patients 2016 · Cochrane Headline outcomes only
  RR 0.89 [0.62, 1.27]
  11 studies · 1691 participants
  Low